Merge Healthcare announced that the company has started the year off with seven new contracts for its clinical trials solutions. These wins reflect continued momentum across all the clinical trials applications, and represent both new and expanded customer relationships.
In addition to the customizable myEDC platform, the Merge solution set for clinical trials includes applications for enterprise Electronic Data Capture (EDC), Interactive Voice and Web Response (IVR/IWR), electronic Patient Reported Outcomes (ePRO) via internet, phone or handheld device, and an endpoint adjudication module. The Merge CIMS platform for managing the imaging component of clinical trials was recently awarded Frost and Sullivan’s 2010 Healthcare Innovation for Medical Imaging Workflow Solutions of the Year. Merge capabilities extend across all stages of clinical trials, international studies, and many clinical specialty trials. The Merge suite of clinical trials solutions will be available for demonstration at the upcoming HIMSS conference February 20 – 24 in Orlando, Florida. Merge can be found at booth #3348.
“We’re thrilled with the recent momentum for this solution set,” said Jeff Surges, Merge CEO. “Clinical trials need efficient electronic workflow via an intuitive interface, and broad interoperability among associated applications, and imaging is a particular challenge. Just as with our iConnect platform for healthcare providers, Merge brings a new value proposition to these customers, and the recent wins show that the clinical trials market recognizes this.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.